S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Banking Nightmare (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Banking Nightmare (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Banking Nightmare (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Banking Nightmare (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Banking Nightmare (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Banking Nightmare (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
BREAKING: Tiny biotech successfully treats blindness (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Banking Nightmare (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Banking Nightmare (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
NASDAQ:EDIT

Editas Medicine - EDIT Stock Forecast, Price & News

$7.46
+0.04 (+0.54%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.29
$7.52
50-Day Range
$7.30
$11.53
52-Week Range
$7.27
$21.59
Volume
1.11 million shs
Average Volume
1.49 million shs
Market Capitalization
$514.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.21 Rating Score
Upside/​Downside
105.5% Upside
$15.33 Price Target
Short Interest
Bearish
27.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.47mentions of Editas Medicine in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$89,105 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.95) to ($2.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

204th out of 1,005 stocks

Biological Products, Except Diagnostic Industry

32nd out of 168 stocks


EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

CRISPR Cas9 Market to 2023-2028
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Editas Medicine Earnings Preview
3 No-Brainer Stocks to Buy Right Now for Less Than $25
Why Editas Medicine's Shares Jumped This Week
Is Editas Medicine Stock a Buy Now?
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
2/22/2023
Today
3/26/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+105.5%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

Net Income
$-220,430,000.00
Net Margins
-1,118.32%
Pretax Margin
-1,118.26%

Debt

Sales & Book Value

Annual Sales
$19.71 million
Book Value
$5.25 per share

Miscellaneous

Free Float
68,073,000
Market Cap
$514.52 million
Optionable
Optionable
Beta
1.90

Key Executives

  • Gilmore O’Neill
    President, Chief Executive Officer & Director
  • Harry R. Gill
    Senior Vice President-Operations
  • Michelle RobertsonMichelle Robertson
    Chief Financial Officer & Treasurer
  • Bruce E. EatonBruce E. Eaton
    Executive VP, Chief Business & Technology Officer
  • Mark S. Shearman
    Chief Scientific Officer & Executive VP













EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2023?

14 analysts have issued twelve-month price objectives for Editas Medicine's stock. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they predict the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 105.5% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 at the beginning of 2023. Since then, EDIT stock has decreased by 15.9% and is now trading at $7.46.
View the best growth stocks for 2023 here
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) released its quarterly earnings data on Wednesday, February, 22nd. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.04. The business had revenue of $6.54 million for the quarter, compared to analyst estimates of $3.76 million. Editas Medicine had a negative trailing twelve-month return on equity of 50.28% and a negative net margin of 1,118.32%. The firm's revenue was down 47.6% on a year-over-year basis. During the same period last year, the business posted ($0.61) earnings per share.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.12%), Dimensional Fund Advisors LP (2.40%), Geode Capital Management LLC (2.01%), JPMorgan Chase & Co. (1.72%), Credit Suisse AG (1.43%) and Two Sigma Investments LP (1.39%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $7.46.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $514.52 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

How many employees does Editas Medicine have?

The company employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 3/26/2023 by MarketBeat.com Staff